{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:14:27Z","timestamp":1793945667667,"version":"4.8.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,12,7]]},"DOI":"10.1038\/s41416-023-02464-y","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:02:14Z","timestamp":1698339734000},"page":"1915-1929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"129","author":[{"given":"Zhijian","family":"Kuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtao","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taige","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-2929","authenticated-orcid":false,"given":"Mingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4471-2186","authenticated-orcid":false,"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3434-4162","authenticated-orcid":false,"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-9037","authenticated-orcid":false,"given":"Meijuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"2464_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2464_CR2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ctrv.2018.07.009","volume":"70","author":"MB Atkins","year":"2018","unstructured":"Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127\u201337.","journal-title":"Cancer Treat Rev"},{"key":"2464_CR3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2016.12.027","volume":"72","author":"B Gershman","year":"2017","unstructured":"Gershman B, Moreira DM, Thompson RH, Boorjian SA, Lohse CM, Costello BA, et al. Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol. 2017;72:300\u20136.","journal-title":"Eur Urol"},{"key":"2464_CR4","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.3390\/cancers13225856","volume":"13","author":"MC Kim","year":"2021","unstructured":"Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, et al. Updates on immunotherapy and immune landscape in renal clear cell carcinoma. Cancers. 2021;13:5856.","journal-title":"Cancers."},{"key":"2464_CR5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/cancers11060830","volume":"11","author":"V Mollica","year":"2019","unstructured":"Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, et al. Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers. 2019;11:830.","journal-title":"Cancers"},{"key":"2464_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15:143.","journal-title":"J Hematol Oncol."},{"key":"2464_CR7","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","volume":"126","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156\u201367.","journal-title":"Cancer."},{"key":"2464_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","volume":"139","author":"R Roskoski Jr","year":"2019","unstructured":"Roskoski R Jr. Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs. Pharm Res. 2019;139:471\u201388.","journal-title":"Pharm Res"},{"key":"2464_CR9","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3390\/ijms19103219","volume":"19","author":"B Garc\u00eda-Reyes","year":"2018","unstructured":"Garc\u00eda-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, et al. The emerging role of cyclin-dependent kinases (CDKs) in pancreatic ductal adenocarcinoma. Int J Mol Sci. 2018;19:3219.","journal-title":"Int J Mol Sci"},{"key":"2464_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","volume":"10","author":"CW Bacon","year":"2019","unstructured":"Bacon CW, D\u2019Orso I. CDK9: a signaling hub for transcriptional control. Transcription. 2019;10:57\u201375.","journal-title":"Transcription."},{"key":"2464_CR11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/15384101.2017.1295177","volume":"16","author":"TC Nepomuceno","year":"2017","unstructured":"Nepomuceno TC, Fernandes VC, Gomes TT, Carvalho RS, Suarez-Kurtz G, Monteiro AN, et al. BRCA1 recruitment to damaged DNA sites is dependent on CDK9. Cell Cycle. 2017;16:665\u201372.","journal-title":"Cell Cycle"},{"key":"2464_CR12","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood.V126.23.4171.4171","volume":"126","author":"P Ghia","year":"2015","unstructured":"Ghia P, Scarfo L, Pathiraja K, Derosier M, Small K, Patton N. A phase 3 study to evaluate the efficacy and safety of dinaciclib compared to ofatumumab in patients with refractory chronic lymphocytic leukemia. Blood. 2015;126:4171.","journal-title":"Blood."},{"key":"2464_CR13","doi-asserted-by":"crossref","first-page":"678559","DOI":"10.3389\/fonc.2021.678559","volume":"11","author":"AT Anshabo","year":"2021","unstructured":"Anshabo AT, Milne R, Wang S, Albrecht H. CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents. Front Oncol. 2021;11:678559.","journal-title":"Front Oncol"},{"key":"2464_CR14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3390\/cancers13092181","volume":"13","author":"R Mandal","year":"2021","unstructured":"Mandal R, Becker S, Strebhardt K. Targeting CDK9 for anti-cancer therapeutics. Cancers. 2021;13:2181.","journal-title":"Cancers."},{"key":"2464_CR15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/14756366.2021.1890726","volume":"36","author":"A Alsfouk","year":"2021","unstructured":"Alsfouk A. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy. J Enzym Inhib Med Chem. 2021;36:693\u2013706.","journal-title":"J Enzym Inhib Med Chem"},{"key":"2464_CR16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3390\/ijms17111849","volume":"17","author":"Y Taniguchi","year":"2016","unstructured":"Taniguchi Y. The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins. Int J Mol Sci. 2016;17:1849.","journal-title":"Int J Mol Sci"},{"key":"2464_CR17","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1159\/000472407","volume":"41","author":"X Wu","year":"2017","unstructured":"Wu X, Liu D, Gao X, Xie F, Tao D, Xiao X, et al. Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma. Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol. 2017;41:1947\u201356.","journal-title":"Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"2464_CR18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00109-011-0837-0","volume":"90","author":"RM Rodriguez","year":"2012","unstructured":"Rodriguez RM, Huidobro C, Urdinguio RG, Mangas C, Soldevilla B, Dominguez G, et al. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med. 2012;90:587\u201395.","journal-title":"J Mol Med"},{"key":"2464_CR19","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati B, Lorenzini E, Ciarrocchi ABRD4. and Cancer: going beyond transcriptional regulation. Mol Cancer. 2018;17:164.","journal-title":"Mol Cancer"},{"key":"2464_CR20","first-page":"e1780v1","volume":"4","author":"J Anaya","year":"2016","unstructured":"Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Prepr. 2016;4:e1780v1.","journal-title":"PeerJ Prepr."},{"key":"2464_CR21","volume":"10","author":"F Chen","year":"2019","unstructured":"Chen F, Chandrashekar DS, Varambally S, Creighton CJ. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10:5679.","journal-title":"Nat Commun"},{"key":"2464_CR22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Pont\u00e9n","year":"2008","unstructured":"Pont\u00e9n F, Jirstr\u00f6m K, Uhlen M. The Human Protein Atlas\u2014a tool for pathology. J Pathol. 2008;216:387\u201393.","journal-title":"J Pathol"},{"key":"2464_CR23","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41596-020-0310-z","volume":"15","author":"JM Dziekan","year":"2020","unstructured":"Dziekan JM, Wirjanata G, Dai L, Go KD, Yu H, Lim YT, et al. Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome. Nat Protoc. 2020;15:1881\u2013921.","journal-title":"Nat Protoc"},{"key":"2464_CR24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ebiom.2018.07.034","volume":"34","author":"J Lu","year":"2018","unstructured":"Lu J, Zhu L, Zheng LP, Cui Q, Zhu HH, Zhao H, et al. Overexpression of ULK1 represents a potential diagnostic marker for clear cell renal carcinoma and the antitumor effects of SBI-0206965. EBioMedicine. 2018;34:85\u201393.","journal-title":"EBioMedicine."},{"key":"2464_CR25","doi-asserted-by":"crossref","first-page":"2004635","DOI":"10.1002\/advs.202004635","volume":"8","author":"HF Shen","year":"2021","unstructured":"Shen HF, Zhang WJ, Huang Y, He YH, Hu GS, Wang L, et al. The dual function of KDM5C in both gene transcriptional activation and repression promotes breast cancer cell growth and tumorigenesis. Adv Sci. 2021;8:2004635.","journal-title":"Adv Sci"},{"key":"2464_CR26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562\u201378.","journal-title":"Nat Protoc"},{"key":"2464_CR27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.molcel.2018.03.006","volume":"70","author":"WW Gao","year":"2018","unstructured":"Gao WW, Xiao RQ, Zhang WJ, Hu YR, Peng BL, Li WJ, et al. JMJD6 licenses ER\u03b1-dependent enhancer and coding gene activation by modulating the recruitment of the CARM1\/MED12 co-activator complex. Mol Cell. 2018;70:340\u201357.e348.","journal-title":"Mol Cell"},{"key":"2464_CR28","doi-asserted-by":"crossref","first-page":"624309","DOI":"10.3389\/fendo.2021.624309","volume":"12","author":"M Jiang","year":"2021","unstructured":"Jiang M, Kuang Z, He Y, Cao Y, Yu T, Cheng J, et al. SNAPIN regulates cell cycle progression to promote pancreatic beta cell growth. Front Endocrinol. 2021;12:624309.","journal-title":"Front Endocrinol"},{"key":"2464_CR29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2016.01.032","volume":"374","author":"H Xiao","year":"2016","unstructured":"Xiao H, Xiao W, Cao J, Li H, Guan W, Guo X, et al. miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. Cancer Lett. 2016;374:107\u201316.","journal-title":"Cancer Lett"},{"key":"2464_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7150\/jca.35426","volume":"11","author":"S Shen","year":"2020","unstructured":"Shen S, Dean DC, Yu Z, Hornicek F, Kan Q, Duan Z. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. J Cancer. 2020;11:132\u201341.","journal-title":"J Cancer"},{"key":"2464_CR31","first-page":"1913","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, et al. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11:1913\u201335.","journal-title":"Am J Cancer Res"},{"key":"2464_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.66","volume":"2","author":"G Polier","year":"2011","unstructured":"Polier G, Ding J, Konkimalla BV, Eick D, Ribeiro N, K\u00f6hler R, et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2011;2:e182.","journal-title":"Cell Death Dis"},{"key":"2464_CR33","doi-asserted-by":"crossref","first-page":"107741","DOI":"10.1016\/j.cclet.2022.107741","volume":"34","author":"M Ao","year":"2022","unstructured":"Ao M, Wu J, Cao Y, He Y, Zhang Y, Gao X, et al. The synthesis of PROTAC molecule and new target KAT6A identification of CDK9 inhibitor iCDK9. Chin Chem Lett. 2022;34:107741.","journal-title":"Chin Chem Lett"},{"key":"2464_CR34","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/med.21581","volume":"39","author":"X Jiang","year":"2019","unstructured":"Jiang X, Yu J, Zhou Z, Kongsted J, Song Y, Pannecouque C, et al. Molecular design opportunities presented by solvent-exposed regions of target proteins. Med Res Rev. 2019;39:2194\u2013238.","journal-title":"Med Res Rev"},{"key":"2464_CR35","unstructured":"Axelsson H, Almqvist H, Seashore-Ludlow B, Lundb\u00e4ck T, Markossian S, Grossman A, et al. Screening for target engagement using the cellular thermal shift assay\u2014CETSA. In: S. Markossian et al. editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004; PMID, 27478247: 873\u201397."},{"key":"2464_CR36","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1128\/MCB.00637-09","volume":"29","author":"K Glover-Cutter","year":"2009","unstructured":"Glover-Cutter K, Larochelle S, Erickson B, Zhang C, Shokat K, Fisher RP, et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol. 2009;29:5455\u201364.","journal-title":"Mol Cell Biol"},{"key":"2464_CR37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nsmb.3233","volume":"23","author":"S Chlamydas","year":"2016","unstructured":"Chlamydas S, Holz H, Samata M, Chelmicki T, Georgiev P, Pelechano V, et al. Functional interplay between MSL1 and CDK7 controls RNA polymerase II Ser5 phosphorylation. Nat Struct Mol Biol. 2016;23:580\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"2464_CR38","doi-asserted-by":"crossref","first-page":"84986","DOI":"10.18632\/oncotarget.18583","volume":"8","author":"N Moreno","year":"2017","unstructured":"Moreno N, Holsten T, Mertins J, Zhogbi A, Johann P, Kool M, et al. Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. Oncotarget. 2017;8:84986\u201395.","journal-title":"Oncotarget."},{"key":"2464_CR39","doi-asserted-by":"crossref","first-page":"23003","DOI":"10.18632\/oncotarget.25190","volume":"9","author":"T Sakaguchi","year":"2018","unstructured":"Sakaguchi T, Yoshino H, Sugita S, Miyamoto K, Yonemori M, Osako Y, et al. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. Oncotarget. 2018;9:23003\u201317.","journal-title":"Oncotarget."},{"key":"2464_CR40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2018.12.022","volume":"39","author":"H Ma","year":"2019","unstructured":"Ma H, Seebacher NA, Hornicek FJ, Duan Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine. 2019;39:182\u201393.","journal-title":"EBioMedicine."},{"key":"2464_CR41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 2020;10:351\u201370.","journal-title":"Cancer Discov"},{"key":"2464_CR42","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","volume":"43","author":"YL Shen","year":"2022","unstructured":"Shen YL, Wang YM, Zhang YX, Ma SJ, Yang LH, Zhao CG, et al. Targeting cyclin-dependent kinase 9 in cancer therapy. Acta Pharm Sin. 2022;43:1633\u201345.","journal-title":"Acta Pharm Sin"},{"key":"2464_CR43","doi-asserted-by":"crossref","first-page":"105826","DOI":"10.1016\/j.intimp.2019.105826","volume":"75","author":"S Xue","year":"2019","unstructured":"Xue S, Shao Q, Zhu LB, Jiang YF, Wang C, Xue B, et al. LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo. Int Immunopharmacol. 2019;75:105826.","journal-title":"Int Immunopharmacol"},{"key":"2464_CR44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","volume":"37","author":"MH Rahaman","year":"2019","unstructured":"Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, et al. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Invest N Drugs. 2019;37:625\u201335.","journal-title":"Invest N Drugs"},{"key":"2464_CR45","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S2152-2650(22)01256-3","volume":"22","author":"F Zhou","year":"2022","unstructured":"Zhou F, Zhao J, Cicic D, Lan J, Lu Q. AML-259 pharmacokinetics and bioequivalence of two formulations of GFH009 maleate injection in Sprague Dawley rats. Clin Lymphoma Myeloma Leuk. 2022;22:S230\u20131.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2464_CR46","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"2464_CR47","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","volume":"28","author":"JR Diamond","year":"2022","unstructured":"Diamond JR, Boni V, Lim E, Nowakowski G, Cordoba R, Morillo D, et al. First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy. Clin Cancer Res. 2022;28:1285\u201393.","journal-title":"Clin Cancer Res"},{"key":"2464_CR48","volume":"7","author":"J Dey","year":"2017","unstructured":"Dey J, Deckwerth TL, Kerwin WS, Casalini JR, Merrell AJ, Grenley MO, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017;7:18007.","journal-title":"Sci Rep"},{"key":"2464_CR49","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/med.21856","volume":"42","author":"D Bhurta","year":"2022","unstructured":"Bhurta D, Bharate SB. Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Med Res Rev. 2022;42:654\u2013709.","journal-title":"Med Res Rev"},{"key":"2464_CR50","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","volume":"83","author":"K Fujinaga","year":"2023","unstructured":"Fujinaga K, Huang F, Peterlin BM. P-TEFb: The master regulator of transcription elongation. Mol Cell. 2023;83:393\u2013403.","journal-title":"Mol Cell"},{"key":"2464_CR51","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S1471-4914(02)02308-0","volume":"8","author":"EA Sausville","year":"2022","unstructured":"Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 2022;8:S32\u20137.","journal-title":"Trends Mol Med"},{"key":"2464_CR52","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1101\/gad.244368.114","volume":"28","author":"CH Huang","year":"2014","unstructured":"Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014;28:1800\u201314.","journal-title":"Genes Dev"},{"key":"2464_CR53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/cc.10.1.14364","volume":"10","author":"SY David","year":"2011","unstructured":"David SY, David C. A role for CDK9-cyclin K in maintaining genome integrity. Cell Cycle. 2011;10:28\u201332.","journal-title":"Cell Cycle"},{"key":"2464_CR54","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/nar\/gkac141","volume":"50","author":"X Liu","year":"2022","unstructured":"Liu X, Zhao B, Shaw TI, Fridley BL, Duckett DR, Tan AC, et al. Summarizing internal dynamics boosts differential analysis and functional interpretation of super enhancers. Nucleic Acids Res. 2022;50:3115\u201327.","journal-title":"Nucleic Acids Res"},{"key":"2464_CR55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel W, Venkatachalam A, Fink A, Hung E, Brachya G, Burstain I, et al. Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell. 2018;175:171\u201385.e125.","journal-title":"Cell."},{"key":"2464_CR56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Signal Transduct Target Ther. 2023;8:113.","journal-title":"Signal Transduct Target Ther"},{"key":"2464_CR57","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-019-1161-9","volume":"21","author":"RP McLaughlin","year":"2019","unstructured":"McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, et al. A kinase inhibitor screen identifies a dual cdc7\/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res. 2019;21:77.","journal-title":"Breast Cancer Res"},{"key":"2464_CR58","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s43018-022-00438-2","volume":"3","author":"YY Chu","year":"2022","unstructured":"Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, et al. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022;3:1211\u201327.","journal-title":"Nat Cancer"},{"key":"2464_CR59","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/CIRCULATIONAHA.120.047239","volume":"142","author":"SY Kim","year":"2020","unstructured":"Kim SY, Zhang X, Schiattarella GG, Altamirano F, Ramos TAR, French KM, et al. Epigenetic reader BRD4 (Bromodomain-Containing Protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function. Circulation. 2020;142:2356\u201370.","journal-title":"Circulation."},{"key":"2464_CR60","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.joca.2020.07.012","volume":"29","author":"T Fukui","year":"2021","unstructured":"Fukui T, Yik JHN, Doyran B, Davis J, Haudenschild AK, Adamopoulos IE, et al. Bromodomain-containing-protein-4 and cyclin-dependent-kinase-9 inhibitors interact synergistically in vitro and combined treatment reduces post-traumatic osteoarthritis severity in mice. Osteoarthr Cartil. 2021;29:68\u201377.","journal-title":"Osteoarthr Cartil"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02464-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02464-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T15:09:10Z","timestamp":1701961750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02464-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,7]]}},"alternative-id":["2464"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02464-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal studies were approved by the Ethics Committee for Animal Experimentation and Animal Welfare at Xiamen University. The study involved no human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}